ZIM Laboratories Limited primarily engages in manufacturing drug formulations and pre-formulation ingredients, serving both domestic and international markets.

The company is undergoing EU-GMP remediation to ensure compliance and resume European market supplies, a top strategic priority.

Financial performance shows a challenge with a 7.8% decline in total operating income for H1FY26 compared to the previous year, highlighting struggles faced in the Nutra segment.

Investments in R&D are significant, accounting for 8.6% of total operating income, with ongoing investment in innovative product development despite revenue pressures.

Strategic initiatives to safeguard its business include utilizing alternate manufacturing sites to maintain operations for key products amid compliance issues.